US 12,215,161 B2
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies
Sheri Moores, Wayne, PA (US); and Smruthi Vijayaraghavan, Spring House, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Filed by JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed on Aug. 3, 2022, as Appl. No. 17/817,295.
Application 17/817,295 is a division of application No. 16/798,662, filed on Feb. 24, 2020, granted, now 11,459,391.
Claims priority of provisional application 62/930,190, filed on Nov. 4, 2019.
Claims priority of provisional application 62/810,716, filed on Feb. 26, 2019.
Prior Publication US 2023/0130600 A1, Apr. 27, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)] 80 Claims
 
1. A method of inducing trogocytosis from a donor cancer cell that expresses EGFR, c-Met, or EGFR and c-Met to an acceptor macrophage cell or an acceptor monocyte cell, the method comprising contacting the donor cancer cell with a bispecific anti-EGFR/c-Met antibody for a time sufficient to induce trogocytosis from the donor cancer cell to the acceptor macrophage cell or the acceptor monocyte cell,
wherein the bispecific anti-EGFR/c-Met antibody comprises:
a first domain that binds EGFR, wherein the first domain comprises a heavy chain complementarity determining region (HCDR1) comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and
a second domain that binds c-Met, wherein the second domain comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 7, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 8, a HCDR3 comprising the amino acid sequence of SEQ ID NO: 9, a LCDR1 comprising the amino acid sequence of SEQ ID NO: 10, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 12.